Fahmy Labs

Fahmy Labs is a biotechnology company and translational research entity focused on the development of advanced biomaterials and nanotechnology for immunotherapy. Based in New Haven, Connecticut, and closely associated with Yale University, the company utilizes a proprietary platform of biodegradable nanogels and artificial antigen-presenting cells (aAPCs) to modulate the immune system. These technologies enable the precise delivery of therapeutic payloads, such as cytokines and small molecules, directly to target immune cells while reducing systemic side effects. Fahmy Labs' innovations have provided the foundational intellectual property for several successful venture-backed startups, including Repertoire Immune Medicines and Modifi Bio. The company's pipeline includes programs targeting oncology, autoimmune disorders, and infectious diseases through synthetic pathogen-mimicking particles. By integrating engineering principles with immunology, Fahmy Labs aims to create next-generation treatments that can either stimulate or suppress immune responses with high specificity.